Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT
Icosapent ethyl was associated with fewer total hospitalizations and fewer days lost due to hospitalization and death, providing additional insights on the effects of icosapent ethyl on patient-centered measures of total disease burden.
Authors
- MICHAEL SZAREK
- M. Mehra
- Steven Ketchum (ORCID: https://orcid.org/0000-0002-8192-1711)
- C. Ballantyne
- M. C. Miller
- Deepak L Bhatt
- Jean-Claude Tardif
Institutions
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Délégation Paris 7 (FR)
- Baylor College of Medicine (US)
- Université Paris Cité (FR)
- University of Utah (US)
- Montreal Heart Institute (CA)
- Assistance Publique – Hôpitaux de Paris (FR)
- Mount Sinai Hospital (US)
- Philadelphia VA Medical Center (US)
- Hôpital Bichat-Claude-Bernard (FR)
- Bridge Pharma (United States) (US)
- Alliance nationale pour les sciences de la vie et de la santé (FR)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1093/eurjpc/zwag040
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00